IDH1 and glioblastoma: We thus selected a homogeneous population of IDH-wildtype glioblastoma in adults, collected the MGMT promoter methylation status when available, and included patients from 2012 to 2018 to ensure that they were treated during the current era with similar surgical, anesthetic and oncological care.